Browse investments

Invest in Rapport Therapeutics, Inc. on Stash

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders.

To buy fractional shares of Rapport Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: RAPP

Rapport Therapeutics, Inc.

$27.66

-10.57%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

RAPP Performance Breakdown

Share Price

$27.66

Today's change

0.51%

Year to date change (YTD)

-1.6%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About RAPP

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Rapport Therapeutics, Inc. Stock Ticker

RAPP

For more information

https://www.rapportrx.com/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Rapport Therapeutics, Inc. on Stash

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders.

To buy fractional shares of Rapport Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Rapport Therapeutics, Inc. stock news

24/7 Wall Street

This Forgotten Mid-Cap Dividend ETF Returned 70% In 5 Years While Paying Monthly Income

The WisdomTree U.S. MidCap Dividend Fund (NYSEARCA:DON) generates income by holding a diversified portfolio of mid-cap dividend-paying stocks.

about 8 hours ago

CNBC

Maduro pleads not guilty, Nvidia's robotaxi play, JPMorgan's 'secret sauce' and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

about 9 hours ago

Business Insider

Trump says the US could pay American oil companies for work in Venezuela

Trump said the US may reimburse oil firms for expanding operations in Venezuela. Venezuela's oil output is low due to sanctions, corruption, and damaged infrastructure.

about 17 hours ago

24/7 Wall Street

iShares Popular Dividend Growth ETF Is More Growth Than Income | DGRO

The iShares Core Dividend Growth ETF ( NYSEARCA:DGRO ) delivers exactly what its name promises: dividend growth, not dividend income.

about 8 hours ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Rapport Therapeutics, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Rapport Therapeutics, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Rapport Therapeutics, Inc.’s price can fluctuate throughout the course of each trading day—when you buy Rapport Therapeutics, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Rapport Therapeutics, Inc. stock price and the Rapport Therapeutics, Inc. news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Rapport Therapeutics, Inc. stock is complete, you'll officially be a shareholder of Rapport Therapeutics, Inc.!